(-)-(S)-2-hydroxy-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-propionamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (-)-(S)-2-hydroxy-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-propionamide
• 英文别名: (2S)-2-hydroxy-N-[(7S)-5-methyl-6-oxo-7H-benzo[d][1]benzazepin-7-yl]propanamide
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: VLCWYNYOVQDNCJ-ZBEGNZNMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (-)-(S)-2-hydroxy-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-propionamide 、 对硝基苯基氯甲酸酯 在 三乙胺 作用下， 以 甲苯 为溶剂， 生成 C₂₅H₂₁N₃O₇
  参考文献：
  名称：

  Novel orally active, dibenzazepinone-based γ-secretase inhibitors

  摘要：

  Structural modifications of the gamma-secretase inhibitor, LY411575, led to a malonamide analogue with potent inhibitory activity in vitro, but disappointing activity in a mouse model of Alzheimer's disease. Identification and replacement of a metabolically labile position provided an improved compound (RIS),(S)-13 with high in vitro activity (IC50 = 1.7 nM), and in vivo activity after oral administration (MED = 3 mg/kg). Further modifications gave an equipotent carbamate analogue 14 with improved molecular properties. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.078
• 作为产物：
  描述：

  (S)-7-氨基-5-甲基-5,7-二氢-6H-二苯并[b,d]氮杂革-6-酮 、 L-乳酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 (-)-(S)-2-hydroxy-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-propionamide
  参考文献：
  名称：

  Novel orally active, dibenzazepinone-based γ-secretase inhibitors

  摘要：

  Structural modifications of the gamma-secretase inhibitor, LY411575, led to a malonamide analogue with potent inhibitory activity in vitro, but disappointing activity in a mouse model of Alzheimer's disease. Identification and replacement of a metabolically labile position provided an improved compound (RIS),(S)-13 with high in vitro activity (IC50 = 1.7 nM), and in vivo activity after oral administration (MED = 3 mg/kg). Further modifications gave an equipotent carbamate analogue 14 with improved molecular properties. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.078

文献信息

• Carbamic acid alkyl ester derivatives
  申请人：Flohr Alexander

  公开号：US20050075327A1

  公开（公告）日：2005-04-07

  The present invention provides compounds of the general formula wherein R 4 is one of the following groups and R 1 , R 2 , R 3 , R 7 , R 8 , and R 9 are as defined in the specification and pharmaceutically acceptable salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds are useful for the treatment of Alzheimer's disease.

  本发明提供了一般公式的化合物其中R4是以下组之一，而R1、R2、R3、R7、R8和R9如规范中定义，以及药用盐、光学纯对映体、外消旋体或它们的二对映异构混合物。这些化合物对治疗阿尔茨海默病有用。
• SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS
  申请人：F. Hoffman-la Roche AG

  公开号：EP1673347A1

  公开（公告）日：2006-06-28
• US7166587B2
  申请人：——

  公开号：US7166587B2

  公开（公告）日：2007-01-23
• [EN] SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS<br/>[FR] DERIVES DE DIBENZO-AZEPINE ET DE BENZO-DIAZEPINE UTILISES EN TANT QU'INHIBITEURS DE LA GAMMA-SECRETASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005040126A1

  公开（公告）日：2005-05-06

  The present invention relates to compounds of the general formula (I) Wherein R1 is -(CHR’)q-aryl or -(CHR')q-heteroaryl, which are unsubstituted or mono, di- or tri-substituted by lower alkyl, lower alkoxy, CF3 or halogen, or is lower alkyl, lower alkenyl, -(CH2)n-Si(CH3)3, -(CH2)n-O-lower alkyl, -(CH2)n-S-lower alkyl, -(CH2)q-cycloalkyl, -(CH2)n-[CH(OH)]m-(CF2)p-CHqF(3-q), or is -(CH2)n-CR2-CF3, wherein the two R radicals form together with the carbon atom a cycloalkyl ring; R' is hydrogen or lower alkyl; n is 1, 2 or 3; in is 0 or 1; p is 0, 1, 2, 3, 4, 5 or 6; q is 0, 1, 2 or 3; R2 is hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, -CH2CF2CF3, CH2CF3, (CH2)2CF3, CF3, CHF2, CF3, CHF2, CH2F, or is aryl, optionally mono, di or tri-substituted by halogen, or is (CH2)nNR5R6, wherein R5 and R6 are independently from each other hydrogen or lower alkyl; R4 is one of the following groups wherein R7is hydrogen, lower akl, -(CH2)n-CF3 or -(CH2)n-cycloalkyl; R8 is hydrogen, lower alkyl, -C(O)-phenyl, -C(O)-lower alkyl, -C(O)O-(CH2)n- cycloalkyl, -C(O)O-(CH2)n-lower alkyl, -C(O)NH-(CH2)n-lower alkyl or -C(O)NH­(CH2).-CyClOalkYl; R9 is hydrogen, lower alkyl, -(CH2)n-cycloalkyl or -(CH2)n-CF3; and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racernates or diastereomeric mixtures thereof for the treatment of Alzheimer's disease..
• Novel orally active, dibenzazepinone-based γ-secretase inhibitors
  作者：Jens-Uwe Peters、Guido Galley、Helmut Jacobsen、Christian Czech、Pascale David-Pierson、Eric A. Kitas、Laurence Ozmen

  DOI：10.1016/j.bmcl.2007.07.078

  日期：2007.11

  Structural modifications of the gamma-secretase inhibitor, LY411575, led to a malonamide analogue with potent inhibitory activity in vitro, but disappointing activity in a mouse model of Alzheimer's disease. Identification and replacement of a metabolically labile position provided an improved compound (RIS),(S)-13 with high in vitro activity (IC50 = 1.7 nM), and in vivo activity after oral administration (MED = 3 mg/kg). Further modifications gave an equipotent carbamate analogue 14 with improved molecular properties. (c) 2007 Elsevier Ltd. All rights reserved.